BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
NCT ID: NCT01241331
Last Updated: 2012-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
233 participants
INTERVENTIONAL
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BLI1100
BLI1100 topical cream
BLI1100
BLI110 topical cream
Vehicle cream
Vehicle topical cream
Vehicle cream
Vehicle topical cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BLI1100
BLI110 topical cream
Vehicle cream
Vehicle topical cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Qualifying number of non-inflammatory lesions
* Qualifying number of inflammatory lesions
Exclusion Criteria
* Using medications that are reported to exacerbate acne
* Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin
* Have a known hypersensitivity or previous allergic reaction to any of the components
* Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
* Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
12 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Braintree Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology Clincal Research
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Dermatology Specialists
Oceanside, California, United States
Horizons Clinical Research Center
Denver, Colorado, United States
North Florida Dermatology Associates
Jacksonville, Florida, United States
Ameriderm Research
Ormond Beach, Florida, United States
Atlanta Dermatology, Vein and Research Center
Alpharetta, Georgia, United States
Peachtree Dermatology Associates Research Center
Atlanta, Georgia, United States
Northwest Clinical Trials
Nampa, Idaho, United States
The Indiana Clinical Trials Center
Plainfield, Indiana, United States
The South Bend Clinic
South Bend, Indiana, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
Clinical Partners
Johnston, Rhode Island, United States
DiscoveResearch
Bryan, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Dermatology Research Center
Salt Lake City, Utah, United States
The Education and Research Foundation
Lynchburg, Virginia, United States
Virginia Clinical Research
Norfolk, Virginia, United States
Premier Clinical Research
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BLI1100-201
Identifier Type: -
Identifier Source: org_study_id